查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2001046

mRNA治療市場：依技術平台、遞送方式及治療應用分類－2026-2032年全球市場預測

mRNA Therapeutics Market by Technology Platform, Delivery Method, Therapeutic Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，mRNA 療法市值將達到 113.3 億美元，到 2026 年將成長至 125.8 億美元，到 2032 年將達到 270.5 億美元，複合年成長率為 13.23%。

主要市場統計數據
基準年 2025 113.3億美元
預計年份：2026年 125.8億美元
預測年份 2032 270.5億美元
複合年成長率 (%) 13.23%

科學突破、對擴大生產規模的需求以及監管趨勢相互交織，標誌著 mRNA 治療領域的關鍵轉折點，迫使人們重新調整研發重點。

mRNA療法領域目前正處於科學檢驗、規模化生產和法規結構演變的三重交匯點，這為研發人員、投資者和衛生監管機構創造了一個獨特的轉折點。核心平台技術的進步表明，編碼遞送治療有效載荷可以觸發持續且可控的生物反應。同時，製劑科學和低溫運輸物流的同步改進正在降低臨床應用的傳統障礙。隨著計劃從概念驗證（PoC）階段進入後期開發階段，相關人員面臨著日益複雜的決策，涵蓋從平台選擇和給藥途徑到特定治療方法的安全性等諸多方面。

平台成熟、製造現代化、監管協調和遞送途徑最佳化正在共同改變 mRNA 療法的臨床和商業策略。

近年來，變革性的變化重新定義了mRNA療法的研發、生產和應用。平台演進是其中最重要的變革之一，脂質體化學和新型載體系統的最佳化顯著改善了體內分佈和耐受性。這項進步拓展了mRNA療法的治療範圍，使其不再局限於疫苗應用，而是涵蓋了慢性病和罕見疾病。同時，生產技術的進步——例如連續生產流程、一次性使用系統和模組化設施設計——縮短了製程轉移前置作業時間，並提高了多產品生產工廠的柔軟性。這些營運方面的改進降低了臨床批次規模化的門檻，並支援更有效率的產品開發週期。

2025 年美國關稅政策的變化將如何影響 mRNA 療法開發中的供應鏈結構、籌資策略和製造地決策？

2025年美國關稅政策發展的累積影響將為mRNA療法供應鏈中的企業帶來一系列營運和策略的考量。關稅變化正在影響關鍵上游工程原料（尤其是脂質、核苷酸和特殊添加劑）的籌資策略，迫使各團隊重新評估供應商所在地和庫存緩衝。為此，許多企業開始實現供應商多元化，以減少對單一國家的依賴；而另一些企業則加快對貿易協定更為有利地區的替代供應商進行認證。這些措施正在重塑採購計劃，並增加供應商審核和品管的複雜性。

策略性細分分析揭示了平台選擇、治療標靶優先排序和交付模式如何共同決定開發路徑和營運需求。

對細分市場動態的深入分析揭示了平台選擇、治療標靶和遞送方法之間的相互作用，從而定義了專案層面的策略和商業化路徑。在考慮技術平台差異化時，脂質奈米顆粒正逐漸成為一種用途廣泛且應用廣泛的載體系統，能夠支援全身和局部遞送目標。基於聚合物的平台因其可調控的釋放動力學和模組化化學結構而備受關注，這些特性可以解決穩定性方面的限制。病毒載體在需要高轉導效率的應用中仍被廣泛研究，尤其是在需要長期表達或細胞特異性靶向的情況下。這些平台選擇促使申辦方將平台選擇與生物學作用機制和生產能力相匹配。

世界各地區域政策、製造業生態系統和法規的多樣性決定了發展和供應連續性策略的順序。

區域趨勢在整個mRNA治療領域對研發重點、監管路徑和商業化策略的製定起著決定性作用。在美洲，市場相關人員必須有效利用一個以完善的臨床網路、活躍的創業投資和私募股權活動以及不斷完善指導方針以適應平台型應用為特徵的生態系統。這些特點為後期臨床試驗和合作創造了有利條件，從而可以加速臨床檢驗並加快與支付方的談判。該地區還擁有一個成熟的契約製造和開發服務（CMOD）生態系統，為申辦方提供了多種無需立即進行資本密集型設施擴建即可擴大生產規模的途徑。

競爭格局顯示，創新主導合作關係、製造領域的垂直整合以及加速從實驗室向臨床實踐過渡的策略夥伴關係正在形成。

mRNA療法領域的競爭格局呈現出科學差異化、合作模式和垂直整合策略交織的態勢。創新公司優先考慮平台新穎性和臨床差異化，以確保獲得利潤豐厚的合作關係和許可協議；而成熟的生物製藥公司則通常透過收購和策略合作，快速獲取尖端技術平台。合約研發生產機構（CDMO）正積極應對這項挑戰，拓展其在製劑、無菌填充和包裝以及低溫運輸物流等方面的能力，從而成為支持臨床項目拓展和商業化推出的重要合作夥伴。

為高階主管提供實際有效的建議，以加快研發進度、增強供應連續性，並使證據產生與支付方的期望保持一致。

產業領導企業可以採取一系列切實可行的措施，在應對技術複雜性和商業性不確定性的同時，加速專案成功。透過優先考慮平台無關的開發路徑，企業可以在分析、對比試驗和監管溝通方面實現跨專案的效率提升。早期投資於製劑和劑量最佳化可以降低後續臨床風險，並提高患者接受度，尤其是在需要重複給藥的適應症。企業還應將供應連續性計劃納入其開發計劃，在關鍵試驗開始前儘早檢驗替代供應商和應急生產安排。這有助於減輕貿易和物流中斷對營運的影響。

透過結合專家訪談、監管審查、技術文獻整合和情境分析等嚴謹且多方面的研究途徑，提取出可操作的產業見解。

本分析的研究基礎包括定性專家訪談、對公開監管文件的審查以及對近期科學文獻的跨學科整合，旨在全面了解mRNA治療生態系統。透過與科學家、製程工程師、監管顧問、生產主管和商業負責人的對話，我們掌握了實際情況並確定了新興的最佳實踐。我們也仔細審查了監管文件和指導資料，以獲得符合當前平台申報和比較生產評估要求的見解。此外，我們也查閱了科學論文和會議論文集，以了解載體化學、給藥途徑和製劑穩定性數據的最新進展。

科學、營運和政策趨勢的最終整合將決定哪些組織能夠將 mRNA 創新轉化為永續的臨床和商業性成功。

mRNA療法領域的特點是技術快速發展、營運模式不斷轉變以及政策環境日新月異，這些因素共同帶來了巨大的機會和複雜的挑戰。載體技術的進步、生產製造的現代化以及遞送途徑的最佳化，拓展了mRNA療法的應用範圍，而監管和貿易趨勢則要求企業進行更精細的風險管理和策略規劃。在這種環境下，能夠將卓越的科學研究能力與切實可行的供應鏈設計、穩健的監管策略以及與早期支付方的合作相結合的企業，更有可能取得成功。將敏捷的創新者與成熟的生產或商業化合作夥伴聯繫起來的協作模式，有望加速mRNA實用化的推廣應用並降低實施風險。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依技術平台分類的mRNA治療藥物市場

  • 脂質奈米顆粒
  • 聚合物基
  • 病毒載體

第9章 mRNA治療藥物市場：依給藥方式分類

  • 肌肉內部
  • 靜脈
  • 皮下

第10章：依治療應用分類的mRNA治療藥物市場

  • 循環系統
  • 感染疾病
  • 腫瘤學
  • 罕見疾病

第11章 mRNA治療藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 mRNA 治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 mRNA治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國mRNA治療藥物市場

第15章：中國的mRNA治療市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Altamira Therapeutics, Inc.
  • Arcturus Therapeutics Holdings, Inc.
  • AstraZeneca plcEthris GmbH
  • BioNTech SE
  • Chimeron Bio, Inc.
  • CureVac NV
  • eTheRNA Immunotherapies NV
  • Genevant Sciences Corporation
  • GlaxoSmithKline plc
  • Gritstone Bio, Inc.
  • Immorna Biotherapeutics, Inc.
  • Kernel Biologics, Inc.
  • Lonza Group Ltd.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • MycoTechnology, Inc.
  • NobleGen, Inc.
  • Novartis AG
  • Nutcracker Therapeutics, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Strand Therapeutics, Inc.
  • Tiba Biotech, LLC
  • VaxEquity Ltd.
Product Code: MRR-205091A88BBD

The mRNA Therapeutics Market was valued at USD 11.33 billion in 2025 and is projected to grow to USD 12.58 billion in 2026, with a CAGR of 13.23%, reaching USD 27.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.33 billion
Estimated Year [2026] USD 12.58 billion
Forecast Year [2032] USD 27.05 billion
CAGR (%) 13.23%

A critical juncture in mRNA therapeutics where scientific breakthroughs, manufacturing scale demands, and regulatory developments converge to reshape development priorities

The field of mRNA therapeutics is now at the intersection of scientific validation, manufacturing scale-up, and evolving regulatory frameworks, creating a unique inflection point for developers, investors, and health authorities. Advances in core platform technologies have demonstrated that encoded delivery of therapeutic payloads can trigger durable and controllable biological responses, while parallel improvements in formulation science and cold-chain logistics have reduced historical barriers to clinical translation. As projects move from proof-of-concept to later-stage development, stakeholders face an increasingly complex set of decisions spanning platform selection, delivery routes, and therapy-specific safety profiles.

Against this backdrop, the industry must reconcile rapid technological progress with the practicalities of commercial execution. Investment priorities are shifting from purely discovery-focused activities to buildouts in manufacturing capacity, quality assurance, and regulatory readiness. Meanwhile, cross-disciplinary collaboration between immunologists, formulation scientists, and process engineers is becoming essential to accelerate timelines and mitigate clinical risk. The introduction of new regulatory guidances and payer discussions further underscores the need for integrated strategies that combine scientific rigor with pragmatic commercialization planning. Ultimately, the current environment rewards organizations that can translate technical differentiation into reproducible clinical outcomes and sustainable supply chains.

Platform maturation, manufacturing modernization, regulatory harmonization, and delivery route optimization are collectively remaking clinical and commercial strategies in mRNA therapeutics

Recent years have witnessed transformative shifts that are redefining how mRNA therapeutics are developed, manufactured, and delivered. Platform evolution is one of the most consequential shifts, as optimizations in lipid nanoparticle chemistry and alternative carrier systems have materially improved biodistribution and tolerability profiles. This progress has, in turn, enabled broader therapeutic ambitions beyond vaccine applications into chronic and rare disease indications. Simultaneously, advances in manufacturing technologies-continuous processing, single-use systems, and modular facility designs-have reduced lead times for process transfer and increased flexibility for multi-product plants. These operational improvements lower the threshold for scaling clinical batches and support more iterative product development cycles.

Regulatory pathways are also evolving from ad hoc, indication-specific guidance toward more standardized frameworks that recognize platform-based similarities. These regulatory trends are encouraging sponsors to design development programs that leverage platform data packages to streamline subsequent product filings. Another major shift is the growing emphasis on delivery modality; intramuscular, intravenous, and subcutaneous routes are now being optimized in parallel for distinct therapeutic goals, which has implications for formulation, dosing strategies, and patient-centric considerations. Finally, commercial models are adapting to a landscape where partnerships between small innovators and large-scale manufacturers are increasingly commonplace, enabling nimble science to access the production capacity and market access expertise necessary for broader patient reach.

How recent United States tariff shifts in 2025 are reshaping supply chain architecture, procurement strategies, and manufacturing footprint decisions across mRNA therapeutic development

The cumulative impact of the United States tariff policy developments in 2025 introduces a series of operational and strategic considerations for organizations involved in the mRNA therapeutics supply chain. Tariff changes have influenced sourcing strategies for key upstream inputs, particularly lipids, nucleotides, and specialized excipients, causing teams to re-evaluate supplier footprints and inventory buffers. In response, many organizations have initiated supplier diversification efforts to reduce single-country exposure, while others have accelerated qualification of alternative vendors in jurisdictions with more favorable trade arrangements. These efforts are reshaping procurement timelines and adding complexity to supplier audits and quality oversight.

Logistics and manufacturing economics have also been affected, as changes in import duties alter landed costs for critical components and finished goods. The result is a recalibration of near-term procurement priorities, with increased emphasis on long-lead contracts and strategic stockpiling for materials that are both specialized and supply-constrained. Companies are also reassessing their manufacturing footprints, weighing the costs and regulatory time associated with relocating or expanding production capacity in multiple trade zones. In parallel, manufacturers are rethinking contracting strategies, including longer-term service agreements with contract development and manufacturing organizations to lock in capacity and mitigate the operational variability introduced by shifting tariff regimes.

Finally, the tariff environment has underscored the importance of policy intelligence as part of commercial planning. Development teams and business leaders are collaborating more closely with trade and legal experts to model scenario impacts on cost structures and timelines. This alignment is prompting organizations to incorporate tariff sensitivity analyses into their go-to-market and supply continuity plans, ensuring that development milestones remain resilient to external trade policy changes.

Strategic segmentation analysis revealing how platform choices, therapeutic target priorities, and delivery modalities jointly determine development paths and operational needs

Insight into segmentation dynamics reveals how platform choices, therapeutic targets, and delivery methods interact to define program-level strategies and commercial pathways. When considering technology platform differentiation, lipid nanoparticles have emerged as a versatile and widely adopted carrier system that supports systemic and local delivery ambitions; polymer-based platforms are attracting interest for tailored release kinetics and modular chemistry that can address stability constraints; viral vectors continue to be explored for applications where high transduction efficiency is essential, particularly when long-term expression or cell-specific targeting is required. Together, these platform options compel sponsors to align platform selection with the biological mechanism of action and manufacturing capabilities.

Therapeutic application segmentation further refines strategic choices. For cardiovascular indications, developers prioritize delivery routes and formulation stability that optimize tissue targeting and repeat dosing tolerability. In infectious diseases, development pathways often emphasize immunogenicity profiles and rapid scalability to address outbreak scenarios. Oncology programs center on tumor targeting, dosing intensity, and combination strategies with existing modalities, while rare diseases frequently demand bespoke development plans that emphasize small-batch manufacturing, high-potency formulation, and patient-centered administration modalities. These therapeutic distinctions drive different risk tolerances, clinical trial designs, and commercialization partners.

Delivery method segmentation is equally consequential, as intramuscular administration supports decentralized delivery and broad immunization campaigns, intravenous approaches enable systemic biodistribution for complex indications, and subcutaneous routes offer patient-friendly dosing possibilities for chronic therapies. Selecting the appropriate delivery modality requires integrating clinical goals, patient experience considerations, and supply-chain realities, since each route carries distinct formulation and stability requirements. The interplay among platform, application, and delivery modality shapes program timelines, clinical endpoint selection, and the types of manufacturing competencies required to execute reliably.

Regional policy, manufacturing ecosystems, and regulatory variability across global territories that shape development sequencing and supply continuity strategies

Regional dynamics play a decisive role in shaping R&D priorities, regulatory pathways, and commercialization strategies across the mRNA therapeutics landscape. In the Americas, market actors must navigate an ecosystem characterized by advanced clinical networks, strong venture and private-equity activity, and regulatory agencies that are refining guidance to accommodate platform-based submissions. These features create fertile ground for late-stage trials and partnerships that can accelerate clinical validation and payer discussions. The region also features a dense contract manufacturing and development services ecosystem, offering sponsors multiple pathways to scale production without immediate capital-intensive facility expansion.

In Europe, Middle East & Africa, regulatory heterogeneity across jurisdictions and the presence of regional health technology assessment frameworks influence go-to-market sequencing and evidence generation priorities. Companies operating in this region often map clinical programs to achieve both centralized regulatory filings where appropriate and tailored national strategies to address reimbursement nuances. Additionally, the region presents collaboration opportunities with academic centers and consortiums that can support translational research and comparative effectiveness studies. In Asia-Pacific, diverse market dynamics include strong government-led manufacturing initiatives, rapidly scaling clinical trial capacity, and interest in domesticizing biomanufacturing capabilities. Policymakers across these markets are increasingly supportive of biotech and advanced therapy investments, creating incentives for local production and regionally focused supply chain strategies.

Across all regions, cross-border collaboration remains a key enabler for advancing complex programs. Regulatory dialogue, manufacturing partnerships, and clinical site networks that span multiple geographies are instrumental for accelerating development timelines and ensuring supply continuity. Effective regional strategies therefore balance global platform validation with locally tailored regulatory and commercial approaches.

Competitive patterns showing innovation-led alliances, vertical integration in manufacturing, and strategic partnerships that accelerate translation from lab to clinic

Competitive behavior in the mRNA therapeutics space reflects a mix of scientific differentiation, partnership models, and vertical integration strategies. Innovators prioritize platform novelty and clinical differentiation to secure advantageous partnering or licensing agreements, while established biopharma players typically pursue acquisition or strategic collaboration to gain rapid access to leading technology platforms. Contract development and manufacturing organizations are responding by expanding capabilities across formulation, aseptic fill-finish, and cold-chain logistics, positioning themselves as essential partners for scaling clinical programs and supporting commercial launches.

Across corporate portfolios, several recurring strategic patterns emerge. First, companies with strong platform IP and robust preclinical evidence are leveraging selective alliances to accelerate translational activities without relinquishing long-term value. Second, organizations focused on chronic disease applications are investing in delivery and formulation differentiation to enable repeated dosing and improve patient adherence. Third, firms targeting oncology and rare disease programs are building close relationships with specialized clinical networks and patient advocacy groups to inform trial design and accelerate enrollment. Finally, manufacturing-focused firms and service providers are carving out competitive moats by offering integrated end-to-end solutions, creating value propositions that reduce the coordination burden for sponsors and compressed timelines for production scale-up.

Practical, high-impact recommendations for executives to accelerate development timelines, strengthen supply continuity, and align evidence generation with payer expectations

Industry leaders can adopt a set of actionable practices to navigate technological complexity and commercial uncertainty while accelerating program success. Prioritizing platform-agnostic development pathways allows organizations to capture cross-program efficiencies in analytics, comparability studies, and regulatory engagements. Investing early in formulation and delivery optimization reduces downstream clinical risk and improves patient acceptability, particularly for indications that require repeat dosing. Companies should also embed supply continuity planning into their development timelines, validating secondary suppliers and contingency manufacturing arrangements well before pivotal studies begin, which mitigates the operational impact of trade or logistics disruptions.

From a go-to-market perspective, establishing strategic partnerships with contract manufacturers and clinical networks can unlock capacity and expedite enrollment without large upfront capital commitments. Leaders should also institutionalize regulatory intelligence functions to track evolving guidances and create modular dossier elements that can be repurposed across indications. Commercial teams must engage with payers and health technology assessors early to shape evidence generation strategies that demonstrate value beyond traditional clinical endpoints. Finally, cultivating cross-functional governance that aligns R&D, manufacturing, regulatory affairs, and commercial planning will accelerate decision-making and ensure that scientific advances translate into executable launch plans and sustainable product lifecycles.

A rigorous, multi-source research approach combining expert interviews, regulatory review, technical literature synthesis, and scenario analysis to surface actionable industry insights

The research underpinning this analysis combined qualitative expert interviews, public regulatory documentation reviews, and cross-disciplinary synthesis of recent scientific literature to ensure a comprehensive view of the mRNA therapeutics ecosystem. Expert conversations were conducted with scientists, process engineers, regulatory advisors, manufacturing executives, and commercial strategists to capture operational realities and identify emergent best practices. Regulatory source materials and guidance documents were examined to align insights with current expectations for platform-based submissions and manufacturing comparability assessments. Scientific publications and conference proceedings were reviewed to capture the latest advances in carrier chemistry, delivery routes, and formulation stability data.

The methodology emphasized triangulation: qualitative inputs were cross-validated against contemporaneous policy shifts and technical publications to reduce bias and surface robust trends. Case-level analyses of representative development programs provided granularity on how platform choice, delivery route, and therapeutic target drive different risk and operational profiles. Supply chain scenario planning and tariff sensitivity reviews were integrated to assess how external policy and logistics factors influence program viability. Throughout, the approach prioritized actionable insights relevant to decision-makers, focusing on practical implications for clinical design, manufacturing strategy, regulatory interactions, and commercial planning.

Final synthesis of scientific, operational, and policy dynamics that determine which organizations will convert mRNA innovation into durable clinical and commercial success

The mRNA therapeutics landscape is characterized by rapid technical progress, shifting operational paradigms, and evolving policy environments that together present both significant opportunities and complex challenges. Progress in carrier technologies, manufacturing modernization, and delivery route optimization has expanded the range of feasible therapeutic applications, while regulatory and trade developments require more sophisticated risk management and strategic planning. Success in this environment will favor organizations that integrate scientific excellence with pragmatic supply chain design, robust regulatory strategies, and early payer engagement. Collaborative approaches that pair nimble innovators with established manufacturing or commercialization partners are likely to accelerate translation and reduce executional risk.

In conclusion, the path forward requires a balanced approach that aligns platform and delivery selection with clinical objectives, anticipates supply and policy headwinds, and builds cross-functional capabilities to translate insights into deliverable programs. Organizations that proactively address these dimensions will be better positioned to convert scientific promise into durable therapeutic and commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. mRNA Therapeutics Market, by Technology Platform

  • 8.1. Lipid Nanoparticles
  • 8.2. Polymer Based
  • 8.3. Viral Vectors

9. mRNA Therapeutics Market, by Delivery Method

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Subcutaneous

10. mRNA Therapeutics Market, by Therapeutic Application

  • 10.1. Cardiovascular
  • 10.2. Infectious Diseases
  • 10.3. Oncology
  • 10.4. Rare Diseases

11. mRNA Therapeutics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. mRNA Therapeutics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. mRNA Therapeutics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States mRNA Therapeutics Market

15. China mRNA Therapeutics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Altamira Therapeutics, Inc.
  • 16.6. Arcturus Therapeutics Holdings, Inc.
  • 16.7. AstraZeneca plcEthris GmbH
  • 16.8. BioNTech SE
  • 16.9. Chimeron Bio, Inc.
  • 16.10. CureVac N.V.
  • 16.11. eTheRNA Immunotherapies N.V.
  • 16.12. Genevant Sciences Corporation
  • 16.13. GlaxoSmithKline plc
  • 16.14. Gritstone Bio, Inc.
  • 16.15. Immorna Biotherapeutics, Inc.
  • 16.16. Kernel Biologics, Inc.
  • 16.17. Lonza Group Ltd.
  • 16.18. Merck & Co., Inc.
  • 16.19. Moderna, Inc.
  • 16.20. MycoTechnology, Inc.
  • 16.21. NobleGen, Inc.
  • 16.22. Novartis AG
  • 16.23. Nutcracker Therapeutics, Inc.
  • 16.24. Pfizer Inc.
  • 16.25. Sanofi S.A.
  • 16.26. Strand Therapeutics, Inc.
  • 16.27. Tiba Biotech, LLC
  • 16.28. VaxEquity Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 46. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 58. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 62. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 63. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 71. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. GCC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GCC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 75. GCC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 76. GCC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. BRICS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. BRICS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 83. BRICS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 84. BRICS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. G7 MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. G7 MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 87. G7 MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 88. G7 MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. NATO MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NATO MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 91. NATO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 92. NATO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 96. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 97. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. CHINA MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. CHINA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 100. CHINA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. CHINA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)